ABSTRACT
Background: Anemia, the decrease of haemoglobin (Hb) concentration is a common disorder complicating pregnancy mostly due to hemodilution, increased demand of iron and poor dietary intake of iron. The aim of this study was to evaluate whether parenteral iron sucrose can be used as an alternative to daily oral iron during pregnancy.Methods: It was a prospective interventional study conducted in the Department of Obstetrics and Gynaecology, Rohilkhand Medical College and Hospital, Bareilly involving pregnant women at 16-24 weeks with Hb 7-10 g/dl. They were randomly allocated to two groups I and II. Group I (oral group) was given oral iron tablets containing 100 mg of elemental iron and 0.5 mg of folic acid as per therapeutic requirement. Group II (parenteral group) were admitted as day care patients and given a total calculated dose of iron sucrose in divided doses of 200 mg each in 100 ml of normal saline as slow intravenous infusion. Hb, packed cell volume (PCV), blood indices were measured at the start, 2 weeks and 4 weeks of treatment. Any side-effects of treatment were also studied.Results: A statistically significant increase in values of Hb, hematocrit, reticulocyte count, red blood cells (RBC's) indices: mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) and mean corpuscular hemoglobin (MCH) coupled with no serious side effects with iron sucrose as compared with oral iron.Conclusions: Intravenous iron sucrose complex is safe, convenient and effective alternative to oral iron for treatment of iron deficiency anemia in pregnancy.
ABSTRACT
Introduction: Labour induction is a clinical intervention thathas the potential to confer major benefits to the mother andnew-born. Study aimed to compare the safety and efficacyof sublingual versus vaginal misoprostol and to evaluatematernal and foetal outcomes after sublingual and vaginalroutes of administration.Material and methods: We conducted a study on inductionof labor with misoprostol on antenatal patients with medicalor obstetric indication who presented in the Department ofObstetrics and Gynaecology, RMCH.Result: There was no significant difference in the demographiccharacteristics between the two groups. The main indicationfor induction in both groups was pregnancy induced HT.Incidence of caesarean section was not significantly differentin the two groups. There was no significant difference inmaternal complications between the two groups.Conclusion: Sublingual misoprostol is as effective and safe asvaginal misoprostol for induction of labor at term.
ABSTRACT
Introduction: Anemia during pregnancy is most commonlycaused by iron deficiency anemia. It can cause severeconsequences for both the mother and developing fetus.Study aimed to compare the safety and efficacy of intravenousferric carboxy maltose (FCM) vs iron sucrose in anaemia inpregnancy.Material and Methods: This is prospective observationalstudy; all women treated with FCM and iron sucrose foranemia during pregnancy between May 2017 and April2018 at our Hospital were included. Total 110 women wereselected. Each study group contained 55 women receivingFCM which was group A and 55 in group B receivingInjection Iron Sucrose between 30 and 36 weeks of pregnancy.Treatment effectiveness was assessed by repeat Hemoglobinand Serum Ferritin level measurement after 2 weeks ofcompletion of therapy. Safety was assessed by analysis ofadverse drug reactions during infusion and 2 hours afterinfusion.Results: Intravenous ferric carboxymaltose infusionsignificantly increased Hemoglobin values compared toIntravenous ferrous sucrose. None of the women developedserious adverse reaction in FCM group.Conclusion: Ferric carboxymaltose can be used safely in Irondeficiency anemia complicating pregnancy.